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Resistance to thyroid hormone (RTH) represents a syndrome in which patients present
elevated circulating thyroid hormones in the presence of non-suppressed TSH. We
report a novel case where a patient with RTH presented a differentiated thyroid cancer.
A19 year-old female had been referred due to thyroid disease that disclosed features
characteristic of a RTH. During the follow up it was detected a follicular tumor that led
to the recommendation for thyroid surgical ablation, where an incidental papillary thyroid
microcarcinoma (mPTC) was found. The increase of thyroglobulin (TG) levels following
thyroid removal referred the patient for radioiodine treatment. Post-treatment, it was
detected jugular adenopathies and the patient was subjected to cervical lymph node
drainage where metastases of the mPTC were found. RTH syndrome was confirmed by
the detection of a THRB germline mutation. A BRAF mutation was also found in the
mPTC but not detected in the follicular adenoma or normal adjacent tissue. The young
age of the patient, the rarity of BRAF mutations in childhood and the high dissemination
of the malignancy, lead us to the speculation that increased TSH stimulation in a RTH
background and oncogenic activation of BRAF could have served as (co) drivers and might
have triggered an advanced stage of the neoplastic disease. These findings together with
a review of published cases add novel information to the management of RTH patients
with differentiated thyroid cancer.
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INTRODUCTION
Thyroid hormone receptors (TRs) belong to the nuclear receptor
superfamily that regulates the activity of thyroid hormone, tri-
iodothyronine (T3), responsible for growth, differentiation and
metabolism. The T3-binding receptors are presented in four
major isoforms: TRα1, TRβ1, TRβ2, and TRβ3. These recep-
tors are codified by THRA and THRB genes present on chro-
mosomes 17 and 3, respectively (Yen, 2001). TRs are able to
bind to specific DNA motifs on the promoters of T3-target
genes, thyroid hormone responsive elements (TREs), leading to
its transcription activation or repression (Guigon and Cheng,
2009).
Mutations in THRB gene lead to a decreased tissue respon-
siveness to thyroid hormones and cause Resistance to thyroid
hormone (RTH) syndrome. Most mutations cluster in a hotspot
area encoding the T3-binding domain that spans exons 8–10 (Yen,
2001). However, a RTH phenotype can also manifest in absence
of THRB alterations (Beck-Peccoz et al., 2006). The disease is
normally inherited in an autosomal dominant manner, and the
mutant receptors usually exert a dominant negative activity over
the wild-type receptors interfering with receptor dimerization
and binding to TREs (Guigon and Cheng, 2009). Clinically, the
hallmark of RTH patients is the presence of high levels of free
thyroid hormones in the presence of measurable TSH. The clin-
ical phenotype of these patients is variable with most patients
presenting mild to moderate symptoms, but the most com-
mon finding is the presence of goiter (Refetoff and Dumitrescu,
2007).
In the last years, a few cases of RTH and differentiated thyroid
cancer have been reported (Taniyama et al., 2001; Kim et al., 2010;
Paragliola et al., 2011; Ramos-Prol et al., 2013; Unluturk et al.,
2013). We present a novel case in which mPTC was associated
with a THRB germline mutation. Due to the unexpected pro-
gression of the mPTC we decided to investigate further the case
looking for molecular alterations relevant for the development,
in this particular case, of a metastatic disease.
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MATERIALS AND METHODS
INFORMED CONSENT
All procedures followed were in accordance with the national
ethical standards previously approved by Local Ethical Review
Committees. Informed consent was obtained from the patient for
being included in the study.
CASE REPORT
In late 1999, a 19-year-old female was referred to the
Endocrinology Department due to thyroid disease. On physical
examination, she presented goiter, a heart rate of 80 beats per
min, no Graves’ ophthalmopathy and no hand tremor although
it was observed palmar hyperhidrosis. The patient had no signs
of emotional disturbances, learning disabilities or mental retar-
dation, though it was noticeable a hyperactive behavior. Clinical
measurements (Figure 1) revealed out of range levels of cir-
culating free thyroxine (T4) (2.87ηg/dL, normal range 0.89–
1.76ηg/dL) and free triiodothyronine T3 (5.3 ρg/mL, normal
range 2.0–4.2 ρg/mL) with the presence of non-suppressed TSH
(1.188μUI/mL, normal range 0.4–4.4μUI/mL). Antithyroid
antibodies were also measured and were at non-detectable lev-
els discarding thyroid autoimmune disease. The patient had
been prescribed with antithyroid therapy (thiamazole 10mg per
day orally) to control the mild hyperthyroidism. Novel eval-
uation presented once more abnormal high levels of free T3
and T4 in the presence of TSH. These results pointed to a case
of central hyperthyroidism. To exclude the presence of a pitu-
itary adenoma, the patient was subjected to a CT scan and
α-GSU was assayed. The coronal CT scan revealed a normal
gland without focal hypodensity or characteristics suggestive of
a pituitary adenoma, and α-GSU dosage was within normal
levels. Taking all this into consideration a diagnosis of RTH was
proposed.
RTH diagnosis was later (2008) confirmed by mutation analy-
sis of the THRB gene that disclosed a germlinemissensemutation.
Both parents were tested for the mutation and no alterations were
detected indicating a de novo origin.
The patient was referred for monitoring and was followed on a
regular basis. In mid 2003, it was noticeable a thyroid enlarge-
ment and palpation exam of the thyroid gland indicated the
presence of solid nodules. Ultrasound imaging confirmed solid,
well circumscribed nodules on the left lobe and a smaller one
on the right side. Fine needle aspiration biopsy (FNAB) of the
nodules indicated follicular tumor(s) and the patient was rec-
ommended for total thyroidectomy. Surgical thyroid ablation was
performed in May 2004. Histological examination of the left lobe
revealed the presence of follicular patterned nodules, the biggest
one, a fetal follicular adenoma with 15mm (Figure 2A). The right
lobe presented a 4mm mPTC (Figure 2B). Post-surgical TSH
level was 58μUI/mL, and the patient started replacement therapy
with levothyroxine. The patient presented a body weight averag-
ing 56Kg, so it started to receive an initial dose of 0.1mg/day
of levothyroxine (≈1.7μg/Kg). The starting dose was based on
the recommended dosage for management of hypothyroidism
according to the American Thyroid Association (ATA) guide-
lines. Since RTH patients require higher doses of replacement
hormone, medication was meant to be adjusted periodically
(using the TSH as a guideline) in order to lower TSH levels
and maintain normal levels of thyroid hormone. However, dur-
ing the adjustment the patient started to present tremors, weight
loss, irritability and sudation. These symptoms led to the deci-
sion of slowing the gradually introduction of supraphysiological
FIGURE 1 | Major events, clinical measurements and therapy management of the patient referring the period on first appearance until the last
appointment. Abbreviations: TMZ, Thiamazole; LT4, Levothyroxine.
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FIGURE 2 | Haematoxylin-eosin stained histological sections of a
follicular adenoma, initially detected in the patient (A); a papillary
microcarcinoma (B); and metastasis of the mPTC in a lymph node
following the cervical drainage (C). The total magnification of the
sections is 200X. Molecular genotyping of the samples detected the
presence of a THRB germline mutation detected in DNA extracted from
blood cells (D). Somatic mutation analysis disclosed the presence of a
BRAF V600E alteration in the mPTC (E, bottom sequence) whereas a
wild-type BRAF sequence was present in the normal adjacent tissue (E,
top sequence).
doses for full replacement. Due to the mPTC incidental find-
ing, thyroglobulin (TG) levels started to be checked. In 2006,
TG levels were slowly increasing and the patient was submit-
ted to radioiodine treatment 3700 MBq (100 mCi). The patient
remained under regular appointments for assessment and TG lev-
els kept being monitored. During 2007, an imagiological study
detected homolateral jugular adenopathies. Evaluation of FNAB
cytologic slides revealed metastases of papillary thyroid carci-
noma (PTC). The patient was subjected to cervical lymph node
drainage. Histological examination found metastases of PTC in
7 out of 17 lymph nodes (Figure 2C). Another treatment with
5500 MBq (150 mCi) was prescribed. Following the second treat-
ment with radioiodine, TG values dropped to residual levels. In
2010, the patient appears to be free of metastatic disease, although
treatment with levothyroxine is still implemented and has reached
0.3mg/day (≈5.35μg/Kg) in order to control TSH levels. The
previous symptoms presented by the patient were attenuated with
the introduction of the beta-blocker, prescribed mainly to con-
trol tachycardia that started to manifest as a consequence of the
levothyroxine dosage.
THYROID ANTIBODIES AND HORMONE LEVELS QUANTIFICATION
Measurements of thyroid autoantibodies were performed by
radioimmunoassay (RIA) (Brahms Diagnostica, Hennigsdorf,
Germany). The thyroid hormone levels were measured by elec-
trochemiluminescence immunoassay (ECLIA) (Roche Diagnostic
GmbH,Mannheim, Germany). Both determinations were carried
out according to the manufacturer specifications.
GENETIC ANALYSIS
Briefly, following whole blood DNA extraction, PCR ampli-
fication was performed and THRB gene was screened for
mutations. Whole blood genomic DNA extraction was prepared
usingNucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany).
Extraction of tumor and adjacent tissue DNA from paraffin-
embedded material was performed using the Invisorb spin tissue
mini kit (Invitek, Berlin, Germany). Tumor and normal tissue
samples were screened for TRHB BRAF, N and H-RAS and
TERT promoter mutation. Amplifications were done using con-
ditions described elsewhere (Trovisco et al., 2005; Rocha et al.,
2007; Vinagre et al., 2013). PCR products were then purified
and bidirectional sequenced on an ABI Prism 3130 xl Automatic
sequencer (Perkin-Elmer, Foster City, USA) using the ABI Prism
Dye Terminator Cycle sequencing kit (Perkin-Elmer).
RESULTS
Direct sequencing of THRB exon 9 showed a germline heterozy-
gous mutation of a single base change in codon 320, Figure 2D.
The mutation leads to an Arginine substitution by a Cysteine
(R320C). The mutation found had been previously associated
to a RTH case and functional characterization revealed that it
induces a reduction of approximately 50% in T3 binding affin-
ity (Burman et al., 1992). Additionally we screened the parents
for the THRB mutation but it was not found, reflecting a de novo
origin. Mutational analysis of BRAF (Figure 2E) in the mPTC
and the lymph node metastasis revealed a Valine to Glutamic acid
substitution at codon 600 (V600E). The BRAF mutation was not
found in the normal adjacent tissue or in the follicular adenoma.
No mutations were found in TERT promoter.
DISCUSSION
RTH corresponds to a syndrome of reduced responsiveness of the
target tissues to thyroid hormone. Refetoff et al. initially described
it in 1967 (Refetoff et al., 1967). In a daily practice, the main
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evidence of RTH still reflects the initial observations, presence of
elevated levels of circulating free T4 and T3 along with normal or
high levels of non-suppressed TSH (Beck-Peccoz et al., 2006). In
the present case, the patient presented this trait, Figure 1, which
pointed to a case of central hyperthyroidism, and RTH syndrome
was thought to be the cause. Clinical manifestations of RTH can
be very heterogeneous (Refetoff and Dumitrescu, 2007), among
the most frequent symptoms of RTH the patient only exhibited,
besides the abnormal hormonal levels, goiter and a hyperactivity
disorder. In RTH the detection of parents and siblings with iden-
tical abnormal thyroid hormone and TSH levels were proposed
by some authors as enough to provide the diagnosis. However,
cases of RTH likely due to de novo mutations, as is the present
case, have been identified in 28% of families with the condition
(Refetoff and Dumitrescu, 2007).
With the identification of THRB gene mutations by Sakurai
et al. (1989), the majority of the cases of RTH syndrome could
be assigned to thyroid hormone nuclear receptor alterations.
Nonetheless, 15% of individuals who present a RTH pheno-
type do not carry mutations in THRB gene. These are desig-
nated as “non-thyroid receptor RTH,” and can present mutations
in selenocysteine insertion sequence-binding protein 2 (SBP2)
or in monocarboxylate transporter 8 (MCT8) genes (Refetoff
and Dumitrescu, 2007). Our patient presented a “classic” RTH
associated with a THRB mutation (R320C) that had been
previously characterized and resulted in decreased T3 binding
affinity (Burman et al., 1992), therefore confirming the advanced
diagnosis. Since we found a mutation in THRB we did not screen
SBP2 and MCT8 for mutations. The THRB mutations detected
in RTH patients cluster mainly in the last 4 exons (7–10) that
code for the hinge region and the T3 hormone ligand-binding
domain of the receptor. These regions correspond to the carboxyl-
terminus of the thyroid hormone receptor β. The majority of
these mutations result in the modification of the ligand-binding
domain site that does not allows the binding of the thyroid
hormone and thus does not function as a proper receptor.
Additionally to the reduction in T3-binding, it can also lead to
impairment in transactivation.
Somatic mutations of THRB have been previously described
in hepatocellular, renal cell carcinoma and other cancers but do
not present a pivotal role in human thyroid carcinogenesis as we
and others, were unable to detect THRB mutations in human
follicular thyroid adenomas, PTC or FTC (Rocha et al., 2007;
Ramos-Prol et al., 2013). Increased frequency of thyroid cancer
was not commonly observed or was not reported in RTH patients.
More recently, cases with thyroid cancer in RTH patients started
to be reported and so far there are already 7 cases in the liter-
ature (Taniyama et al., 2001; Kim et al., 2010; Paragliola et al.,
2011; Ramos-Prol et al., 2013; Unluturk et al., 2013); reviewed
in Table 1. THRB mutations can lead to increased TSH levels
Table 1 | Review of known cases of RTH patients with differentiated thyroid cancer.
References Age Gender Tumor Treatment of DTC follow-up
Histology Size Genotyping 1. RTH
2. DTC
Taniyama et al., 2001 46 F FvPTC 5mm THRB R249Q 1. Methimazole NA
2. Subtotal thyroidectomy
Kim et al., 2010 38 F PTC 4mm* THRB M310T 1. Levothyroxin NA
2. Total thyroidectomy
Paragliola et al., 2011 48 M PTC 24mm ND 1. Levothyroxin 9.5 years
2. Total thyroidectomy In remission
Paragliola et al., 2011 63 M PTC 6mm THRB P453T 1. Levothyroxin 5 years
2. Total thyroidectomy In remission
Unluturk et al., 2013 29 F PTC 8mm THRB T334C 1. Levothyroxin 21 years
2. Subtotal thyroidectomy (1st
approach)
2. Completion thyroidectomy and
radioiodine (2nd approach)
In remission
Unluturk et al., 2013 33 F PTC 12mm ND 1. Levothyroxin 1 year
2. Total thyroidectomy and radioiodine In remission
Ramos-Prol et al., 2013 9 F PTC 24mm* THRB R243W 1. TRIAC and levothyroxine 2 years
2. Total thyroidectomy and radioiodine In remission
Current case 19 F PTC 4mm THRB R320C 1. Levothyroxin 6 years
2. Total thyroidectomy and radioiodine In remission
RTH, Resistance to thyroid hormone syndrome; DTC, Differentiated thyroid cancer; FvPTC, Follicular variant of papillary thyroid carcinoma; PTC, Papillary thyroid
carcinoma; ND, Not detected; NA, Not available; TRIAC, Triiodothyroacetic acid; *multifocal tumors.
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by ultimately disrupting the hypothalamic-pituitary-thyroid axis
tight regulation and TSH has long been known to increase adeny-
late cyclase activity leading to cAMP production and promoting
cell growth (Dumont et al., 1992).
In the present case, an occult mPTCwas found after thyroidec-
tomy. The mPTC is a very common condition, being a frequent
incidental finding in thyroid gland removal for other reasons, or
in autopsy (Rosai et al., 2003). Although mPTC’s usually show
an indolent behavior, some (3–15%) have the capability to spread
to regional lymph nodes, and exceptionally metastasize to other
organs (Simpson and Albores-Saavedra, 2007). Generally, mPTC
developed in adolescence and young adulthood tend to present a
growing rate similar to the thyroid gland, unless additional events
occur and cause an increase in their growth rate (Rosai et al.,
2003). It is well established that neck lymph node metastases are
common in young individuals with papillary thyroid carcinoma
and this fact contributes to the idea that thyroid cancer aris-
ing in a young patient is associated with a higher aggressiveness.
However, most of the evidence in record concerns clinically evi-
dent papillary carcinomas. Regarding our case, we are referring
an incidental papillary microcarcinoma, where it was demon-
strated that age was not a significant factor affecting lymph node
metastasis (Gulben et al., 2008). So, in addition to the contin-
ual thyrotrophic TSH stimulation we sought to identify what
could have been an additional event(s) in our case. We evaluated
the frequent oncogenic mutation in genes N-RAS, H-RAS, and
BRAF as potential relevant factors additionally to the TSH stim-
ulation. We also analyzed TERT promoter mutations, a recent
molecular change associated to thyroid tumors (Vinagre et al.,
2013). Molecular analysis determined the presence of a BRAF
mutation in the mPTC as well as in the respective metastases.
Such finding fits with the papillary growth pattern, and is in
agreement with the high frequency of BRAF mutations (43%)
we detected in a series of mPTC displaying papillary pattern
(Trovisco et al., 2005). Conversely, BRAF mutation is associated
with older patients, and tends to be rare in young adulthood PTC
tumors (Trovisco et al., 2005; Fugazzola et al., 2006). Together,
the young age of the patient and the high dissemination of the
malignancy, lead us to suggest that increased TSH stimulation
in a RTH background and oncogenic activation of BRAF could
have served as (co) drivers. We are now aware that the manage-
ment of the patient was not the most adequate as TSH levels still
remained elevated although it is well established thatmaintenance
of a suppression of TSH is challenging in this cases (Unluturk
et al., 2013). The continual TSH stimulation as a consequence of
the inadequate hormone replacement might have been a major
tumor growth contributor. This stimulation probably causes the
enlargement of the thyroid gland and the goitrogenic effect seen
in patients with RTH syndrome and TSH-secreting pituitary ade-
nomas. Cases of pituitary TSH-secreting adenomas in association
with thyroid cancer have also been reported in the literature
(for a review, please refer to reference Unluturk et al., 2013).
These associations between TSH stimulation and thyroid cancer
could also be supported by the studies referring the association
between thyroid cancer and serum TSH concentration, and the
possible role of TSH in the progression of differentiated thy-
roid cancer (for a thorough review, see reference Boelaert, 2009).
Additional interesting observation refers to the possible role of
thyroid-stimulating antibodies simulating TSH effect in Grave’s
disease associated thyroid cancer. Although it remains a matter of
controversy, studies have suggested an increase in aggressiveness
(frequent distant metastases) of PTC and FTC in Grave’s disease
patients (Filetti et al., 1988; Yano et al., 2007).
Summing up, we speculate that the concurrence of TRHB
mutation, high TSH levels and BRAF mutation might have acted
toward the malignant transformation and the aggressiveness of
the mPTC in the present case. All the other cases reviewed did
not present tumor genotyping so we cannot infer about the BRAF
role in the other reported patients. Aggressive treatment can be
an option to prevent tumor recurrence and persistence in the
absence of an ideal TSH suppression, as was the case we report.
Finally, we believe this subject will continue to be debatable, and
new cases and novel presentations should be reported as so far
the outcome of the reported cases have not been unfavorable
and they will bring novel knowledge and information to this
issue.
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